Department of Respiratory Sciences, University of Leicester, Leicester LE1 9HN, UK.
Medicina (Kaunas). 2020 Aug 12;56(8):405. doi: 10.3390/medicina56080405.
Asthma is an important respiratory illness. Though pharmacological and biological treatment is well established and is staged according to endotypes and their responses to treatment, novel avenues are being explored. Our focus is complement. In this viewpoint, we evaluate the approach to target complement in this complex hypersensitivity reaction that develops chronicity and has a personal-as well as a societal-cost.
哮喘是一种重要的呼吸道疾病。虽然药理学和生物学治疗已经得到很好的建立，并根据表型及其对治疗的反应进行分期，但新的途径正在探索中。我们关注的是补体。在这篇观点文章中，我们评估了针对这种复杂超敏反应中补体的靶标治疗方法，这种超敏反应会发展为慢性疾病，给个人和社会带来成本。
